EN DE
Watch Synergy Innovation Co. Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Synergy Innovation Co. Ltd (048870) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Synergy Innovation Co. Ltd stock KRW 777, price KRW 1,372, that is 43.4% below the price, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7048870000

SI Synergy Innovation Co. Ltd logo Broad data Nov 5, 2026

Synergy Innovation Co. Ltd

048870 · KQ
Very expensive, weak quality

Our calculation puts a fair price 43% below what the stock costs today.

Low debt
Generates free cash flow
Ranks above peers (13/14)
Broad data
Quality 46/100
Mixed Growth (revenue 5y +10.4 %/yr in KRW)
Thin margins · 8.6% net margin (TTM)
Fair value 776.84 KRW · Strongly overvalued
Narrow moat 43/100 · thin data
Watch Synergy Innovation Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

6,320 KRW 1,352 KRW Fair Value 776.84 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range 1,352 KRW – 6,320 KRW · fair‑value band 563.94 KRW – 1,108 KRW · the 1,372 KRW price screens above the 776.84 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.

Follow Synergy Innovation Co. in your weekly email

Every Wednesday you see whether Synergy Innovation Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Synergy Innovation Co., Ltd. engages in the research and development, and investment of generic and new drugs, medical devices, and health functional foods in South Korea.

Show moreShow less

It produces and sells various culture media for hospitals, pharmaceuticals, and food/cosmetics; manufactures synergy innovation " universal transport solutions (SI-UTS); and invests and develops in various fields comprising microorganism, bacteria, and virus.

The company also provides pharmaceutical formulations; and develops non-vascular stents. Synergy Innovation Co., Ltd. was founded in 1998 and is headquartered in Seongnam-Si, South Korea.

Stock analysis

Synergy Innovation Co. Ltd (048870) currently trades at 1,372 KRW, while our model-based Fair Value estimate is 776.84 KRW, 43% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 1,895 KRW per share, and 2 of the 26 models we run sit above the 1,372 KRW price.

Bear case: the Earnings-Based group reads lowest at 554.00 KRW, and 24 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: 563.94 KRW (bear) to 1,108 KRW (bull), the price of 1,372 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Synergy Innovation Co. Ltd reported revenue of 113B KRW in FY2025 versus 30.7B KRW in FY2021, a compound +38.5%/yr. Reported net income was 3.0B KRW in FY2025, compounding −14.8%/yr from FY2021.

Key figures

Market cap 121B KRW (≈ $89.4M) Micro · P/E ratio 12.4 · P/S ratio 1.06 · EPS (TTM) 113.80 KRW · Dividend yield 1.2% · Net margin 8.6% · Return on equity 6.8% · Return on assets (EBIT) 5.4% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).

What moves the price

The share trades about 46% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −43%, 048870 screens richer than that median.

Fair Value models

Bear 563.94 KRW Fair Value 776.84 KRW Bull 1,108 KRW
Price 1,372 KRW · Downside -43.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (97.59 KRW per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF 556.56 KRW 829.29 KRW 1,256 KRW 79
Growth DCF 546.85 KRW 776.84 KRW 1,108 KRW 77
Owner Earnings 391.20 KRW 544.45 KRW 784.00 KRW 76
All 26 models by family
DCF Models
FCF DCF 556.56 KRW 829.29 KRW 1,256 KRW 79
Owner Earnings 391.20 KRW 544.45 KRW 784.00 KRW 76
5Y Revenue Exit 648.35 KRW 1,049 KRW 1,610 KRW 70
5Y EBITDA Exit 773.37 KRW 1,316 KRW 2,020 KRW 73
5Y P/E Exit 644.32 KRW 1,041 KRW 1,508 KRW 69
10Y Revenue Exit 590.24 KRW 934.88 KRW 1,492 KRW 64
10Y EBITDA Exit 680.09 KRW 1,112 KRW 1,807 KRW 66
10Y P/E Exit 602.90 KRW 929.17 KRW 1,413 KRW 62
Earnings-Based
Graham-Dodd 232.41 KRW 1,215 KRW 1,681 KRW 63
Lynch FV 333.27 KRW 476.10 KRW 618.93 KRW 61
PEG = 1.0 333.27 KRW 476.10 KRW 618.93 KRW 57
EPV 580.22 KRW 631.90 KRW 674.46 KRW 73
Dividend Discount
Gordon GGM 34.99 KRW 60.96 KRW 81.59 KRW 68
DDM Multi-Stage 34.99 KRW 56.68 KRW 65.35 KRW 67
Multiples
P/E Multiple 563.94 KRW 751.92 KRW 939.90 KRW 63
P/S Multiple 435.77 KRW 581.03 KRW 726.29 KRW 57
P/B Multiple 3,657 KRW 4,876 KRW 6,095 KRW 55
EV/EBIT 649.98 KRW 898.86 KRW 1,148 KRW 65
EV/EBITDA 692.21 KRW 955.18 KRW 1,218 KRW 67
EV/Revenue 436.23 KRW 664.62 KRW 893.00 KRW 52
Asset-Based
NCAV (Graham) 1,251 KRW 1,895 KRW 2,368 KRW 54
Growth DCF
Growth DCF 546.85 KRW 776.84 KRW 1,108 KRW 77
Rev-Margin DCF 648.35 KRW 1,034 KRW 1,552 KRW 71
Economic Profit
Residual Income 1,299 KRW 1,368 KRW 1,523 KRW 76
ROIC Compounder 580.22 KRW 631.90 KRW 674.46 KRW 71
Growth Earnings
Growth-Adj P/E 509.15 KRW 727.36 KRW 945.56 KRW 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 22
How much profit the company makes from its sales and capital
Quality Growth 55
Are margins and returns getting better?
Cashflow 55
Do the profits arrive as real cash?
Financial strength 65
Debt, balance sheet and risk of trouble
Investment 44
Does it invest with discipline instead of growing at any price?
Low Volatility 72
How calm the share price moves, does not count
Price momentum 10
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 38
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 69/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+24.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.4%
Start year 2020 (pandemic). Over 10 years: +22.5% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.7%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+24.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+23.1%
Dividend (yield on the price)1.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−11.1% vs −19.7%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 17%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−10.7%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −12.5% a year for the price.

048870 screens overvalued: fair value 43% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Synergy Innovation Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 46 · Above median
Fair Value upside −44.2% · Above median
Profitability
Return on equity (12 months) 6.8% · Top 25%
Return on assets 3.3% · Above median
Net margin (12 months) 32.0% · Top 25%
Operating margin (12 months) 17.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 13.4% · Above median
Dividend yield (12 months) 1.2% · Above median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 12.4× · Cheapest 25%
P/B 0.58× · Cheapest 25%
P/S (12 months) 3.90× · Cheaper than median
Price / free cash flow (fiscal year) 58.4× · Pricier than median
EV/EBITDA 9.5× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)67 · sector 0
PAST (return on equity)27 · sector 0
HEALTH (low debt)98 · sector 97
DIVIDEND (yield)24 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 048870
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 048870
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 048870
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 048870
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 048870
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 048870
argenx SE ARGX $927.21 $908.40 −2% vs 048870
CSL Limited CSL A$200.77 A$183.04 −9% vs 048870
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 048870
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 048870

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Synergy Innovation Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Synergy Innovation Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/048870

Frequently asked questions

Is Synergy Innovation Co. Ltd (048870) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 776.84 KRW versus a price of 1,372 KRW, about 43% lower (overvalued).
What is the fair value of 048870?
Our model-based fair value for Synergy Innovation Co. Ltd is 776.84 KRW (as of Nov 5, 2026), built from audited fundamentals. The current price: 1,372 KRW.
What is the quality score of 048870?
Synergy Innovation Co. Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Synergy Innovation Co. Ltd (048870)?
Our model-based price target is the fair value of 776.84 KRW (as of Nov 5, 2026) from 26 valuation models. Cautious scenario 563.94 KRW, optimistic scenario 1,108 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Synergy Innovation Co. Ltd stock forecast for 2026?
Our models put fair value at 776.84 KRW, about 43% lower versus a price of 1,372 KRW (overvalued). Cautious scenario 563.94 KRW, optimistic scenario 1,108 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Synergy Innovation Co. Ltd (048870)?
Synergy Innovation Co. Ltd reported trailing-twelve-month revenue of about 117B KRW (latest available figure, as of Nov 5, 2026).
Does Synergy Innovation Co. Ltd pay a dividend?
Synergy Innovation Co. Ltd currently shows a dividend yield of 1.19% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Synergy Innovation Co. Ltd (048870)?
Synergy Innovation Co. Ltd has a dividend yield of 1.2%.
What growth is priced into Synergy Innovation Co. Ltd (048870)?
For today's price to be fair in a discounted-cash-flow model, Synergy Innovation Co. Ltd would have to grow free cash flow by -10.7 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.4 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 048870 use?
Our models discount Synergy Innovation Co. Ltd at 11.6 %: a base by market capitalisation (micro), damped by beta 0.08, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Synergy Innovation Co. Ltd that is -10.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Synergy Innovation Co. Ltd (048870) delivered so far?
Over the past 5 years revenue at Synergy Innovation Co. Ltd grew +10.4 % a year. The price currently implies free-cash-flow growth of -10.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Synergy Innovation Co. Ltd (048870) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Synergy Innovation Co. Ltd (-10.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Synergy Innovation Co. Ltd (048870)?
The free-cash-flow yield on the price is 6.45 %: that much free cash flow Synergy Innovation Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Synergy Innovation Co. Ltd (048870)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Synergy Innovation Co. Ltd it is 776.84 KRW per share (as of Nov 5, 2026), against a price of 1,372 KRW. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Synergy Innovation Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 048870 trades above its calculated fair value: price 1,372 KRW, fair value 776.84 KRW, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 048870?
No. The price is what the market pays today (1,372 KRW); the fair value is what the company's own numbers justify (776.84 KRW). For Synergy Innovation Co. Ltd the two are 595.16 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Synergy Innovation Co. Ltd worth?
The market values Synergy Innovation Co. Ltd at about 121B KRW (market capitalisation, as of Nov 5, 2026). Per share that is 1,372 KRW; our models calculate a fair value of 776.84 KRW per share.
What do the bullish and bearish scenarios say about 048870?
Our models span a range for Synergy Innovation Co. Ltd: cautious scenario 563.94 KRW, base 776.84 KRW, optimistic 1,108 KRW per share (as of Nov 5, 2026, price 1,372 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 048870?
Synergy Innovation Co. Ltd trades at a price-to-earnings ratio of 12.4 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 776.84 KRW is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2016 to 2025), reported earnings: 42.0. Other multiples: P/B 0.6, P/S 3.9, EV/EBITDA 9.5.
How solid is the balance sheet of Synergy Innovation Co. Ltd (048870)?
Balance-sheet figures for Synergy Innovation Co. Ltd (as of Nov 5, 2026): return on equity 6.8%, debt of 0.03 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 048870 from its 52-week high?
Synergy Innovation Co. Ltd trades at 1,372 KRW, about 46% below its 52-week high of 2,530 KRW and 1% above the low of 1,352 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 776.84 KRW is for.
Which stocks are comparable to Synergy Innovation Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Synergy Innovation Co. Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price 1,372 KRW, calculated fair value 776.84 KRW (−43%), Quality Score 46/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 048870 calculated?
We run Synergy Innovation Co. Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 776.84 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Synergy Innovation Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Synergy Innovation Co. Ltd (048870)?
The closing price on Nov 9, 2026 was 1,372 KRW. Our model-based fair value is 776.84 KRW, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Synergy Innovation Co. Ltd right now?
The price sits above even our optimistic bull case (1,108 KRW). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (563.94 KRW to 1,108 KRW) leaves room in how you read the outcome.

Key figures of Synergy Innovation Co. Ltd

How large is the market capitalisation of Synergy Innovation Co. Ltd (048870)?
The market capitalisation of Synergy Innovation Co. Ltd is 121B KRW (≈ $89.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Synergy Innovation Co. Ltd (048870)?
The price-to-sales ratio of Synergy Innovation Co. Ltd is 1.06 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Synergy Innovation Co. Ltd (048870)?
Earnings per share at Synergy Innovation Co. Ltd are 113.80 KRW (price ÷ EPS = P/E 12.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Synergy Innovation Co. Ltd (048870)?
The dividend yield of Synergy Innovation Co. Ltd is 1.2% (payout 14.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Synergy Innovation Co. Ltd (048870)?
The net margin of Synergy Innovation Co. Ltd is 8.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Synergy Innovation Co. Ltd (048870)?
The return on equity (ROE) of Synergy Innovation Co. Ltd is 6.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Synergy Innovation Co. Ltd (048870)?
On an EBIT basis the return on assets of Synergy Innovation Co. Ltd is 5.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Synergy Innovation Co. Ltd (048870)?
The operating margin of Synergy Innovation Co. Ltd is 17.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Synergy Innovation Co. Ltd (048870)?
Revenue at Synergy Innovation Co. Ltd is growing +13.4% versus a year earlier (3y avg +9.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Synergy Innovation Co. Ltd (048870)?
Earnings per share at Synergy Innovation Co. Ltd are growing +293% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Synergy Innovation Co. Ltd (048870) carry?
The net debt of Synergy Innovation Co. Ltd is 31.6B KRW (fiscal year 2022, ≈ 4.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Synergy Innovation Co. Ltd in the live analysis

One click puts Synergy Innovation Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.